Incyclix Bio
NC - DurhamBiotechnology
Focus: Incyclix Bio is a Series B-stage biotechnology company focused on precision cancer treatments targeting aberrant cell proliferation drivers. Based in Durham, NC, the company operates as a pre-revenue biotech entity still in early clinical development.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
0
About Incyclix Bio
AI assessmentNot HiringNo open roles listed right now. Follow Incyclix Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
INX-315
Breast CancerClinical Trials (1)
NCT05735080Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Phase 1/2Help build intelligence for Incyclix Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.